Additionally, emerging evidence supports the use of novel antidiabetic agents such as GLP‐1 RAs and SGLT2 inhibitors, which may reduce cardiovascular and infection‐related complications due to their glucose‐independent cardioprotective and anti‐inflammatory effects. The gene discussed is SLC5A2; the disease is infection.